From GlobeNewswire: 2025-04-28 08:22:00

The Point of Care Diagnostics Market is growing due to increased infectious diseases, including HIV, malaria, and tuberculosis. The market is expected to reach US$ 82.95 Billion by 2028 with a CAGR of 12.7%. The need for rapid and accessible diagnostic tools for infectious diseases is driving market growth, especially in North America, Europe, and APAC.

Healthcare systems are adopting rapid diagnostics in emergency and remote settings to provide quick clinical decisions. Point-of-care testing allows for faster diagnosis and treatment, especially for conditions like sepsis and respiratory infections. In the US, around 38.4 million people had diabetes in 2021, emphasizing the need for regular monitoring in underserved areas.

Key players in the Point of Care Diagnostics Market include F. Hoffmann-La Roche Ltd, Abbott, and Johnson & Johnson. Recent partnerships are enhancing diagnostics, like DexCom integrating glucose monitoring with smart rings. A less invasive test for detecting womb cancer, WID-easy, was introduced in the UK for women over 45. The market is segmented by product, prescription mode, end user, and region.

The shift towards point-of-care diagnostics is making healthcare more accessible and cost-effective. These advancements extend diagnostics beyond hospitals to rural clinics and homes, improving outcomes for patients. The trend towards rapid, personalized, and accessible diagnostics is transforming the healthcare industry. Stay updated on the latest trends in the Point of Care Diagnostics Market for valuable insights.



Read more at GlobeNewswire: Point of Care Diagnostics Market Size to Reach $82.95 Bn by